These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [The pharmaco-economics of the treatment of arterial hypertension: data and controversies]. Rorive G; Delporte JP Bull Mem Acad R Med Belg; 1998; 153(7-9):317-21; discussion 322-4. PubMed ID: 10100395 [TBL] [Abstract][Full Text] [Related]
4. Hypertension, a health economics perspective. Alcocer L; Cueto L Ther Adv Cardiovasc Dis; 2008 Jun; 2(3):147-55. PubMed ID: 19124418 [TBL] [Abstract][Full Text] [Related]
6. Angiotensin receptor blockers: impact on costs of care. Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacotherapy of hypertension. How much can safely be saved?]. Anlauf M MMW Fortschr Med; 2004 Apr; 146(15):57-8. PubMed ID: 15373022 [No Abstract] [Full Text] [Related]
8. [Fully possible to reduce the costs of hypertension treatment]. Wettermark B; Angman A; Hjemdahl P Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013 [No Abstract] [Full Text] [Related]
9. [Cost-effectiveness of treatment of high blood pressure with losartan in Denmark]. Keiding H; Hildebrandt P; Burke T; Carides GW Ugeskr Laeger; 2006 Oct; 168(42):3623-6. PubMed ID: 17069726 [TBL] [Abstract][Full Text] [Related]
10. Health economic issues and the future treatment and management of hypertension. Giles TD AAPPO J; 1994; 4(4):27-8, 30, 33-5. PubMed ID: 10150589 [No Abstract] [Full Text] [Related]
11. Differences in medical expenditure according to drug prices. Ueshima H Hypertens Res; 2006 May; 29(5):301-2. PubMed ID: 16832148 [No Abstract] [Full Text] [Related]
12. [A reply on subsidizing of antihypertensive agents: the problem is exceptional undertreatment of hypertension]. Willenheimer R; Nyström F; Berggren B; Lindström T; Cizinsky S; Weiss L Lakartidningen; 2008 Oct 22-28; 105(43):3055-6. PubMed ID: 19024623 [No Abstract] [Full Text] [Related]
13. [The cost/benefit of antihypertensive therapy]. Pessina AC Ann Ital Med Int; 1995 Oct; 10 Suppl():96S-98S. PubMed ID: 8562277 [TBL] [Abstract][Full Text] [Related]
16. Cost as a factor in the treatment of hypertension. Dart RA Contemp Intern Med; 1995 Feb; 7(2):10-4. PubMed ID: 10150334 [No Abstract] [Full Text] [Related]
17. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Caro JJ; Lee K Curr Hypertens Rep; 2002 Dec; 4(6):418. PubMed ID: 12419167 [No Abstract] [Full Text] [Related]
19. Moderately elevated blood pressure. A report from SBU, the Swedish Council on Technology Assessment in Health Care. J Intern Med Suppl; 1995; 737():1-225. PubMed ID: 9043531 [No Abstract] [Full Text] [Related]
20. Cost effective analyses in the treatment of high blood pressure. Fletcher A J Hum Hypertens; 1992 Dec; 6(6):437-45. PubMed ID: 1296007 [No Abstract] [Full Text] [Related] [Next] [New Search]